PURPOSE: We have noted that hypermethylation at GSTP1 in the preoperative serum of men with localized prostate cancer predicts early prostate specific antigen failure following surgical treatment. In this study we investigated the hypermethylation profile of several genes in the serum of men with localized and hormone refractory prostate cancer. MATERIALS AND METHODS: We assayed the serum of 192 men with clinically localized prostate cancer and 18 with hormone refractory metastatic disease. A total of 35 serum samples from patients with negative prostate biopsy served as a negative control. CpG Island hypermethylation status of certain genes was assessed, including MDR1, EDNRB, CD44, NEP, PTGS2, RASSF1A, RAR-beta and ESR1. The results of hypermethylation at GSTP1 were included from a previous study. RESULTS: CpG island hypermethylation at MDR1 was positive in 38.2% of cases without PSA recurrence and in 16.1% of those with biochemical recurrence after radical prostatectomy. DNA hypermethylation at the remaining 7 gene loci was not detected in the serum of patients with localized prostate cancer. In serum from metastatic prostate cancer cases CpG island hypermethylation was detected at MDR1 in 15 (83.3%), EDNRB in 9 (50%), RAR-beta in 7 (38.9%), GTSP1 in 5 (27.8%) and NEP or RASSF1A in 3 (16.7%). CpG island hypermethylation at CD44, PTGS2 or ESR was not detected in any samples. All histologically normal cases were negative for CpG island hypermethylation. CONCLUSIONS: DNA hypermethylation at MDR1 was detected in cases of localized prostate cancer. CpG island hypermethylation at several gene loci was detected in men with advanced disease. No single gene was consistently observed to be hypermethylated in men with hormone refractory disease. These results suggest that the CpG island hypermethylation status of a defined panel of genes may be a useful biomarker in men with hormone refractory prostate cancer.
PURPOSE: We have noted that hypermethylation at GSTP1 in the preoperative serum of men with localized prostate cancer predicts early prostate specific antigenfailure following surgical treatment. In this study we investigated the hypermethylation profile of several genes in the serum of men with localized and hormone refractory prostate cancer. MATERIALS AND METHODS: We assayed the serum of 192 men with clinically localized prostate cancer and 18 with hormone refractory metastatic disease. A total of 35 serum samples from patients with negative prostate biopsy served as a negative control. CpG Island hypermethylation status of certain genes was assessed, including MDR1, EDNRB, CD44, NEP, PTGS2, RASSF1A, RAR-beta and ESR1. The results of hypermethylation at GSTP1 were included from a previous study. RESULTS: CpG island hypermethylation at MDR1 was positive in 38.2% of cases without PSA recurrence and in 16.1% of those with biochemical recurrence after radical prostatectomy. DNA hypermethylation at the remaining 7 gene loci was not detected in the serum of patients with localized prostate cancer. In serum from metastatic prostate cancer cases CpG island hypermethylation was detected at MDR1 in 15 (83.3%), EDNRB in 9 (50%), RAR-beta in 7 (38.9%), GTSP1 in 5 (27.8%) and NEP or RASSF1A in 3 (16.7%). CpG island hypermethylation at CD44, PTGS2 or ESR was not detected in any samples. All histologically normal cases were negative for CpG island hypermethylation. CONCLUSIONS: DNA hypermethylation at MDR1 was detected in cases of localized prostate cancer. CpG island hypermethylation at several gene loci was detected in men with advanced disease. No single gene was consistently observed to be hypermethylated in men with hormone refractory disease. These results suggest that the CpG island hypermethylation status of a defined panel of genes may be a useful biomarker in men with hormone refractory prostate cancer.
Authors: Mohsen Karimi; Sofia Johansson; Dirk Stach; Martin Corcoran; Dan Grandér; Martin Schalling; Georgy Bakalkin; Frank Lyko; Catharina Larsson; Tomas J Ekström Journal: Exp Cell Res Date: 2006-04-19 Impact factor: 3.905
Authors: Takuji Mori; Steven J O'Day; Naoyuki Umetani; Steve R Martinez; Minoru Kitago; Kazuo Koyanagi; Christine Kuo; Teh-Ling Takeshima; Robert Milford; He-Jing Wang; Vu D Vu; Sandy L Nguyen; Dave S B Hoon Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Kazuo Koyanagi; Takuji Mori; Steven J O'Day; Steve R Martinez; He-Jing Wang; Dave S B Hoon Journal: Cancer Res Date: 2006-06-15 Impact factor: 12.701
Authors: Patrick J Bastian; Ganesh S Palapattu; Xiaohui Lin; Srinivasan Yegnasubramanian; Leslie A Mangold; Bruce Trock; Mario A Eisenberger; Alan W Partin; William G Nelson Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Patrick J Bastian; Jörg Ellinger; Axel Wellmann; Nicolas Wernert; Lukas C Heukamp; Stefan C Müller; Alexander von Ruecker Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Karen Woodson; John Gillespie; Jeffrey Hanson; Mike Emmert-Buck; John M Phillips; W Marston Linehan; Joseph A Tangrea Journal: Prostate Date: 2004-06-15 Impact factor: 4.104
Authors: Srinivasan Yegnasubramanian; Jeanne Kowalski; Mark L Gonzalgo; Marianna Zahurak; Steven Piantadosi; Patrick C Walsh; G Steven Bova; Angelo M De Marzo; William B Isaacs; William G Nelson Journal: Cancer Res Date: 2004-03-15 Impact factor: 12.701
Authors: Carmen Jerónimo; Rui Henrique; Mohammad O Hoque; Franclim R Ribeiro; Jorge Oliveira; Daniel Fonseca; Manuel R Teixeira; Carlos Lopes; David Sidransky Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Srinivasan Yegnasubramanian; Xiaohui Lin; Michael C Haffner; Angelo M DeMarzo; William G Nelson Journal: Nucleic Acids Res Date: 2006-02-09 Impact factor: 16.971
Authors: Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo Journal: Adv Anat Pathol Date: 2008-11 Impact factor: 3.875
Authors: Mukesh Verma; Scott Rogers; Rao L Divi; Sheri D Schully; Stefanie Nelson; L Joseph Su; Sharon A Ross; Susan Pilch; Deborah M Winn; Muin J Khoury Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-12-10 Impact factor: 4.254